Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)
Abstract Background Concerns have been raised over the safety of methylphenidate (MPH), with regard to adverse effects on growth and blood pressure. Our study investigates whether, and to what extent, methylphenidate use in boys with ADHD is associated with having low body mass index (BMI), having l...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-10-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12888-018-1884-7 |
id |
doaj-f1dbef68d02e4a6abd99f21944f43373 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Suzanne McCarthy Antje Neubert Kenneth K. C. Man Tobias Banaschewski Jan Buitelaar Sara Carucci David Coghill Marina Danckaerts Bruno Falissard Peter Garas Alexander Häge Chris Hollis Sarah Inglis Hanna Kovshoff Elizabeth Liddle Konstantin Mechler Peter Nagy Eric Rosenthal Robert Schlack Edmund Sonuga-Barke Alessandro Zuddas Ian C. K. Wong |
spellingShingle |
Suzanne McCarthy Antje Neubert Kenneth K. C. Man Tobias Banaschewski Jan Buitelaar Sara Carucci David Coghill Marina Danckaerts Bruno Falissard Peter Garas Alexander Häge Chris Hollis Sarah Inglis Hanna Kovshoff Elizabeth Liddle Konstantin Mechler Peter Nagy Eric Rosenthal Robert Schlack Edmund Sonuga-Barke Alessandro Zuddas Ian C. K. Wong Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) BMC Psychiatry ADHD Methylphenidate Safety Growth BMI Blood pressure |
author_facet |
Suzanne McCarthy Antje Neubert Kenneth K. C. Man Tobias Banaschewski Jan Buitelaar Sara Carucci David Coghill Marina Danckaerts Bruno Falissard Peter Garas Alexander Häge Chris Hollis Sarah Inglis Hanna Kovshoff Elizabeth Liddle Konstantin Mechler Peter Nagy Eric Rosenthal Robert Schlack Edmund Sonuga-Barke Alessandro Zuddas Ian C. K. Wong |
author_sort |
Suzanne McCarthy |
title |
Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) |
title_short |
Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) |
title_full |
Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) |
title_fullStr |
Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) |
title_full_unstemmed |
Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) |
title_sort |
effects of long-term methylphenidate use on growth and blood pressure: results of the german health interview and examination survey for children and adolescents (kiggs) |
publisher |
BMC |
series |
BMC Psychiatry |
issn |
1471-244X |
publishDate |
2018-10-01 |
description |
Abstract Background Concerns have been raised over the safety of methylphenidate (MPH), with regard to adverse effects on growth and blood pressure. Our study investigates whether, and to what extent, methylphenidate use in boys with ADHD is associated with having low body mass index (BMI), having low height, and increased systolic and diastolic blood pressure. Methods Data used for this study stem from the German KiGGS dataset. Three different groups of boys aged 6–15 years were included in the analysis: ADHD patients who used MPH for less than 12 months; ADHD patients who used MPH for 12 months or more; and ADHD patients without current MPH treatment. Each of these three groups was compared to a non-ADHD control group regarding low weight (BMI ≤ 3rd percentile), low height (≤3rd percentile) and raised systolic and diastolic blood pressure. For growth outcomes, boys were categorized according to age (< 11 years/≥11 years, to account for pubertal maturation). Multivariable logistic regression was conducted to test for associations. Results 4244 boys were included in the study; MPH < 12 months: n = 65 (n = 36 < 11 years), MPH ≥ 12 months: n = 53 (n = 22 < 11 years), ADHD controls: n = 320 (n = 132 < 11 years), non-ADHD controls: n = 3806 (n = 2003 < 11 years). Pre-pubertal boys with MPH use less than 12 months and pubertal/postpubertal boys with MPH use of 12 months or greater were significantly more likely to have a BMI ≤ 3rd percentile compared to non-ADHD controls. Boys from the ADHD control group were significantly less likely to have a raised systolic blood pressure compared to non-ADHD controls. Beyond that, no significant between group differences were observed for any other growth and BP parameter. Conclusion The analyses of the KiGGS dataset showed that MPH use in boys with ADHD is associated with low BMI. However, this effect was only observed in certain groups. Furthermore, our analysis was unable to confirm that MPH use is also associated with low height (≤3rd percentile) and changes in blood pressure. |
topic |
ADHD Methylphenidate Safety Growth BMI Blood pressure |
url |
http://link.springer.com/article/10.1186/s12888-018-1884-7 |
work_keys_str_mv |
AT suzannemccarthy effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT antjeneubert effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT kennethkcman effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT tobiasbanaschewski effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT janbuitelaar effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT saracarucci effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT davidcoghill effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT marinadanckaerts effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT brunofalissard effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT petergaras effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT alexanderhage effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT chrishollis effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT sarahinglis effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT hannakovshoff effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT elizabethliddle effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT konstantinmechler effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT peternagy effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT ericrosenthal effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT robertschlack effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT edmundsonugabarke effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT alessandrozuddas effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs AT ianckwong effectsoflongtermmethylphenidateuseongrowthandbloodpressureresultsofthegermanhealthinterviewandexaminationsurveyforchildrenandadolescentskiggs |
_version_ |
1725174312581726208 |
spelling |
doaj-f1dbef68d02e4a6abd99f21944f433732020-11-25T01:10:30ZengBMCBMC Psychiatry1471-244X2018-10-0118111010.1186/s12888-018-1884-7Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)Suzanne McCarthy0Antje Neubert1Kenneth K. C. Man2Tobias Banaschewski3Jan Buitelaar4Sara Carucci5David Coghill6Marina Danckaerts7Bruno Falissard8Peter Garas9Alexander Häge10Chris Hollis11Sarah Inglis12Hanna Kovshoff13Elizabeth Liddle14Konstantin Mechler15Peter Nagy16Eric Rosenthal17Robert Schlack18Edmund Sonuga-Barke19Alessandro Zuddas20Ian C. K. Wong21School of Pharmacy, University College CorkDepartment of Paediatrics and Adolescents Medicine, University Hospital ErlangenCentre for Paediatric Pharmacy Research, Research Department of Practice and Policy, UCL School of PharmacyDepartment of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of HeidelbergDepartment of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, & Karakter Child and Adolescent Psychiatry University CentreChild and Adolescent Neuropsychiatry Unit, Department of Biomedical Science, University of Cagliari & “A. Cao” Pediatric Hospital, Brotzu Hospital TrustDepartments of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of MelbourneDepartment of Child and Adolescent Psychiatry, University Psychiatric CenterUniversity Paris-Sud, Univ. Paris-Descartes, AP-HP, INSERM U1178Vadaskert Child and Adolescent Psychiatric HospitalDepartment of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of HeidelbergDivision of Psychiatry and Applied Psychology, Institute of Mental Health, School of Medicine, University of NottinghamTayside Clinical Trials Unit, University of DundeeDepartment of Psychology, University of SouthamptonDivision of Psychiatry and Applied Psychology, Institute of Mental Health, School of Medicine, University of NottinghamDepartment of Child & Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of HeidelbergVadaskert Child and Adolescent Psychiatric HospitalDepartment of Paediatric Cardiology, Evelina Children’s Hospital, St Thomas’ HospitalUnit of Mental Health Department of Epidemiology and Health Reporting, Robert Koch InstituteDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry, King’s College LondonChild and Adolescent Neuropsychiatry Unit, Department of Biomedical Science, University of Cagliari & “A. Cao” Pediatric Hospital, Brotzu Hospital TrustCentre for Paediatric Pharmacy Research, Research Department of Practice and Policy, UCL School of PharmacyAbstract Background Concerns have been raised over the safety of methylphenidate (MPH), with regard to adverse effects on growth and blood pressure. Our study investigates whether, and to what extent, methylphenidate use in boys with ADHD is associated with having low body mass index (BMI), having low height, and increased systolic and diastolic blood pressure. Methods Data used for this study stem from the German KiGGS dataset. Three different groups of boys aged 6–15 years were included in the analysis: ADHD patients who used MPH for less than 12 months; ADHD patients who used MPH for 12 months or more; and ADHD patients without current MPH treatment. Each of these three groups was compared to a non-ADHD control group regarding low weight (BMI ≤ 3rd percentile), low height (≤3rd percentile) and raised systolic and diastolic blood pressure. For growth outcomes, boys were categorized according to age (< 11 years/≥11 years, to account for pubertal maturation). Multivariable logistic regression was conducted to test for associations. Results 4244 boys were included in the study; MPH < 12 months: n = 65 (n = 36 < 11 years), MPH ≥ 12 months: n = 53 (n = 22 < 11 years), ADHD controls: n = 320 (n = 132 < 11 years), non-ADHD controls: n = 3806 (n = 2003 < 11 years). Pre-pubertal boys with MPH use less than 12 months and pubertal/postpubertal boys with MPH use of 12 months or greater were significantly more likely to have a BMI ≤ 3rd percentile compared to non-ADHD controls. Boys from the ADHD control group were significantly less likely to have a raised systolic blood pressure compared to non-ADHD controls. Beyond that, no significant between group differences were observed for any other growth and BP parameter. Conclusion The analyses of the KiGGS dataset showed that MPH use in boys with ADHD is associated with low BMI. However, this effect was only observed in certain groups. Furthermore, our analysis was unable to confirm that MPH use is also associated with low height (≤3rd percentile) and changes in blood pressure.http://link.springer.com/article/10.1186/s12888-018-1884-7ADHDMethylphenidateSafetyGrowthBMIBlood pressure |